2020
DOI: 10.1016/j.prro.2020.02.014
|View full text |Cite
|
Sign up to set email alerts
|

Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 22 publications
0
8
0
Order By: Relevance
“…However, the model was not sensitive to fluctuations in costs associated with complications from PRT. Although the study by Pan et al 21 provides the most granular data on intensity-modulated radiotherapy complications, a recent study 35 of complications associated with other radiation modalities used for prostate cancer using Medicare fees found similar costs. Furthermore, costs will invariably vary across different health care systems.…”
Section: Discussionmentioning
confidence: 99%
“…However, the model was not sensitive to fluctuations in costs associated with complications from PRT. Although the study by Pan et al 21 provides the most granular data on intensity-modulated radiotherapy complications, a recent study 35 of complications associated with other radiation modalities used for prostate cancer using Medicare fees found similar costs. Furthermore, costs will invariably vary across different health care systems.…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, there have been increasing needs and trends to use large administrative health data sets to construct a cohort of people with a specific health condition and follow them longitudinally to capture real-world health care utilization and costs. For PCa, recent costing studies based on such data and design have measured and compared the costs by factors such as age, disease state or stage, tumor grade, treatment strategy, and/or care phase (including the diagnosis phase before diagnosis) [ 21 , 22 , 23 , 24 , 25 ]. However, previous data were either relatively outdated and thus not well representative of the most recent PCa treatment guidelines or only measured costs by some factors instead of all.…”
Section: Introductionmentioning
confidence: 99%
“…Promotion of AS is an important strategy to reduce the treatment costs for low‐risk PCa. To date, several studies have compared AS with other treatments using a mathematical model 5–10 or electronic health records (EHR) such as Medicare 11–13 . However, no study has analyzed the outcomes using actual treatment trends in Japan.…”
Section: Introductionmentioning
confidence: 99%
“…To date, several studies have compared AS with other treatments using a mathematical model [5][6][7][8][9][10] or electronic health records (EHR) such as Medicare. [11][12][13] However, no study has analyzed the outcomes using actual treatment trends in Japan. Thus, this study aimed to evaluate the costeffectiveness of AS compared with that of robot-assisted laparoscopic prostatectomy (RALP), intensity-modulated radiation therapy (IMRT), brachytherapy (BT), and HT for men diagnosed with low-risk localized PCa in Japan.…”
Section: Introductionmentioning
confidence: 99%